PMID- 17404783
OWN - NLM
STAT- MEDLINE
DCOM- 20080205
LR  - 20220331
IS  - 0770-3198 (Print)
IS  - 0770-3198 (Linking)
VI  - 26
IP  - 12
DP  - 2007 Dec
TI  - Effects of an educational-behavioral joint protection program on people with 
      moderate to severe rheumatoid arthritis: a randomized controlled trial.
PG  - 2043-2050
LID - 10.1007/s10067-007-0615-0 [doi]
AB  - The aim of this study was to asses the effects on pain, disability, and health 
      status of an educational-behavioral joint protection program in a group of 
      moderate-severe rheumatoid arthritis (RA) patients. Eighty-five subjects with RA 
      in treatment with anti-tumor necrosis factor alpha (TNFalpha) drugs (infliximab) 
      were enrolled into the study and randomized into either an experimental group 
      (46, EG) or a control group (39, CG). We organized four EG meetings, which 
      included information on pathophysiology and evolution of RA, joint protection 
      during normal activities of daily living, suggestions on how to adapt the 
      surrounding environment, and self-learning exercises to perform at home. 
      Sociodemographic characteristics and degree of knowledge of the disease, measured 
      by the Health Service Interview (HSI), were recorded at baseline. The outcome 
      measures included the Visual Analogue Scale (VAS), the Arthritis Impact 
      Measurement Scale 2 (AIMS2), and the Health Assessment Questionnaire (HAQ), which 
      were administered at the beginning and end of the trial. Thirty-six patients from 
      the EG (7 men and 29 women; mean age 54.2 years) and 34 from the CG (6 men and 28 
      women; mean age 52.2 years) completed the trial. No statistical differences in 
      baseline evaluations were found between the two groups. According to the answers 
      given on the HSI, the majority of our patients had poor knowledge of RA and its 
      consequences. After a mean time of 8 months, the patients receiving educational 
      training displayed a significant decrease, compared to the CG, in the VAS (p = 
      0.001), HAQ (p = 0.000), and physical (p =0.000), symptoms (p = 0.049), and 
      social interaction (p = 0.045) scores on the AIMS2, but not in other items. Our 
      study showed that 8 months after attending an educational-behavioral joint 
      protection program, subjects with moderate-severe RA presented less pain and 
      disability and thus an enhanced health status. This approach may efficiently 
      complement drug therapy in these patients.
FAU - Masiero, Stefano
AU  - Masiero S
AD  - Department of Rehabilitation Medicine, School of Medicine, University of Padova, 
      Padova, Italy. stef.masiero@unipd.it.
AD  - Servizio di Riabilitazione, Universita-Azienda Ospedaliera of Padova, Via 
      Giustiniani 2, 35128, Padova, Italy. stef.masiero@unipd.it.
FAU - Boniolo, Anna
AU  - Boniolo A
AD  - Department of Rehabilitation Medicine, School of Medicine, University of Padova, 
      Padova, Italy.
FAU - Wassermann, Lidia
AU  - Wassermann L
AD  - Department of Rehabilitation Medicine, School of Medicine, University of Padova, 
      Padova, Italy.
FAU - Machiedo, Hela
AU  - Machiedo H
AD  - Department of Rehabilitation Medicine, School of Medicine, University of Padova, 
      Padova, Italy.
FAU - Volante, Daniela
AU  - Volante D
AD  - Department of Rheumatology, School of Medicine, University of Padova, Padova, 
      Italy.
FAU - Punzi, Leonardo
AU  - Punzi L
AD  - Department of Rheumatology, School of Medicine, University of Padova, Padova, 
      Italy.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20070403
PL  - Germany
TA  - Clin Rheumatol
JT  - Clinical rheumatology
JID - 8211469
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - B72HH48FLU (Infliximab)
SB  - IM
MH  - Activities of Daily Living
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Antirheumatic Agents/therapeutic use
MH  - Arthritis, Rheumatoid/drug therapy/psychology/*rehabilitation
MH  - Behavior Therapy/*methods
MH  - *Disability Evaluation
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Infliximab
MH  - Male
MH  - Middle Aged
MH  - Patient Education as Topic/*methods
MH  - *Program Evaluation
MH  - Retrospective Studies
MH  - Severity of Illness Index
MH  - Surveys and Questionnaires
MH  - Treatment Outcome
MH  - Tumor Necrosis Factor-alpha/antagonists & inhibitors
EDAT- 2007/04/04 09:00
MHDA- 2008/02/06 09:00
CRDT- 2007/04/04 09:00
PHST- 2006/12/18 00:00 [received]
PHST- 2007/03/19 00:00 [accepted]
PHST- 2007/04/04 09:00 [pubmed]
PHST- 2008/02/06 09:00 [medline]
PHST- 2007/04/04 09:00 [entrez]
AID - 10.1007/s10067-007-0615-0 [pii]
AID - 10.1007/s10067-007-0615-0 [doi]
PST - ppublish
SO  - Clin Rheumatol. 2007 Dec;26(12):2043-2050. doi: 10.1007/s10067-007-0615-0. Epub 
      2007 Apr 3.